Valuation : Corcept Therapeutics Incorporated

Market Cap 12.51B 10.76B 10.13B 9.23B 17.28B 1,190B 17.34B 120B 46.42B 606B 46.96B 45.94B 1,921B P/E 2026 *
56.2x
P/E 2027 * 27x
Enterprise Value 12.51B 10.76B 10.13B 9.23B 17.28B 1,190B 17.34B 120B 46.42B 606B 46.96B 45.94B 1,921B EV / Sales 2026 *
10.9x
EV / Sales 2027 * 7.34x
Free-Float
65.9%
Yield 2026 *
-
Yield 2027 * -
1 day+1.51%
1 week+4.77%
Current month+2.07%
1 month+4.45%
3 months+49.31%
6 months+240.39%
Current year+232.47%
1 week 108.25
Extreme 108.25
117.5
1 month 108.25
Extreme 108.25
126.38
Current year 28.66
Extreme 28.6601
126.38
1 year 28.66
Extreme 28.6601
126.38
3 years 20.84
Extreme 20.84
126.38
5 years 15.82
Extreme 15.825
126.38
10 years 5.42
Extreme 5.42
126.38
Manager TitleAgeSince
Chief Executive Officer 68 1998-12-31
Director of Finance/CFO 49 2021-02-28
Chief Tech/Sci/R&D Officer 48 2024-01-31
Director TitleAgeSince
Director/Board Member 68 1998-12-31
Chairman 82 1998-12-31
Director/Board Member 71 2004-06-30
Date Insider Type Main position Quantity % Market Cap. Importance
9/2/26 Tax

Chief Financial Officer

-102 0.0001%
9/2/26 Tax

Executive/Senior Manager

-117 0.0001%
9/2/26 Tax

Company Secretary

-91 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
+1.51%+4.77%+61.30%+251.24% 12.51B
+0.03%-3.09%+49.77%+91.69% 1,002B
-0.76%-2.95%+50.93%+66.34% 644B
+0.86%-4.13%+19.24%+68.37% 443B
-0.47%-2.69%+30.36%+36.63% 343B
+1.34%-13.63%+12.59%+28.43% 262B
-0.31%-4.08%-2.22%+10.93% 245B
-0.48%-11.65%+39.75%+50.82% 212B
-0.03%-3.95%-17.51%-57.65% 199B
-0.68%-2.65%+25.82%+91.64% 181B
Average +0.43%-4.02%+27.00%+63.85% 354.22B
Weighted average by Cap. +0.45%-4.21%+32.39%+58.32%

Financials

2026 *2027 *
Net sales 1.15B 986M 929M 846M 1.58B 109B 1.59B 11.01B 4.25B 55.56B 4.3B 4.21B 176B 1.7B 1.47B 1.38B 1.26B 2.35B 162B 2.36B 16.37B 6.33B 82.65B 6.4B 6.26B 262B
Net income 242M 208M 196M 178M 334M 22.98B 335M 2.32B 896M 11.71B 907M 887M 37.1B 594M 511M 481M 438M 820M 56.49B 823M 5.7B 2.2B 28.78B 2.23B 2.18B 91.17B
Net Debt - -
Logo Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. It is also conducting advanced clinical trials in patients with solid tumors, Amyotrophic Lateral Sclerosis (ALS) and liver disease. It operates through the discovery, development and commercialization of the pharmaceutical products segment. It sells Korlym and a generic version of Korlym in the United States using sales representatives to call on physicians caring for patients with hypercortisolism (Cushing’s syndrome). The Company's portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. It sells and distributes Lifyorli in the United States. It is developing its proprietary, selective cortisol modulator, relacorilant, as a treatment for patients with hypercortisolism.
Employees
730
Date Price Change Volume
26-09-09 US$115.70 +1.51% 572,048
26-09-08 US$113.98 +2.11% 1,045,845
26-09-04 US$111.62 -1.05% 604,556
26-09-03 US$112.80 +2.15% 611,214
26-09-02 US$110.43 -2.60% 960,829
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
115.70USD
Average target price
141.00USD
Spread / Average Target
+21.87%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CORT Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!